Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT07380984
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
A Prospective Study to Evaluate the Efficacy and Safety of PD-1 Monoclonal Antibody-based Stratified Targeted Therapy Combined With Concurrent Radiotherapy for Patients With Treatment-naive Early-stage Nasal-type NK/T-cell Lymphoma
Sponsor: Ruijin Hospital
Conditions
Natural Killer/T-cell Lymphoma
Interventions
Chidamide PD-1 antibody golidocitinib radiotherapy
Updated 1 time since 2026 Last updated: Feb 25, 2026 Started: Feb 1, 2026 Primary completion: Feb 1, 2029 Completion: Feb 1, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Natural Killer/T-cell Lymphoma and is currently actively recruiting participants. Ruijin Hospital leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Ruijin Hospital
Data source: Ruijin Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.